Physician profile
Robert T Nelson
NPI 1902860380
$9,158.78
in general payments reported to CMS, 2019-2025
41 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,002 · 2020: $473 · 2021: $1,245 · 2022: $1,251 · 2023: $1,315 · 2024: $852 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753 · Travel and Lodging: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.33 |
| Travel and Lodging | $435.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,455.14 | 2019-2025 | |
| Janssen Biotech, INC. | $1,058.78 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $910.53 | 2019-2024 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $734.52 | 2021-2025 | |
| Astellas Pharma US INC | $719.57 | 2019-2025 | Xtandi, Veozah, Myrbetriq |
| Abbvie INC. | $546.18 | 2019-2025 | |
| Blue Earth Diagnostics | $350.67 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $334.24 | 2023-2025 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $316.78 | 2021-2025 | Pylarify |
| Antares Pharma, INC. | $301.04 | 2019-2025 | Xyosted |
| Pfizer INC. | $293.71 | 2019-2025 | |
| Amgen INC. | $274.61 | 2019-2023 | Prolia |
| Endo Pharmaceuticals INC. | $251.92 | 2019-2023 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $182.09 | 2020-2024 | Keytruda, Welireg, Lynparza |
| Myovant Sciences INC. | $116.67 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $110.00 | 2025 | Xiaflex, Aveed |
| Urovant Sciences INC | $108.03 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $99.05 | 2024-2025 | Adstiladrin |
| Urogen Pharma, INC. | $95.34 | 2023-2024 | Jelmyto |
| Tempus Ai, INC | $81.19 | 2024-2025 | Xt Cdx |
| Clarus Therapeutics INC. | $71.88 | 2021 | |
| Boston Scientific Corporation | $69.88 | 2019-2025 | Rezum Generator |
| Ambu INC. | $63.88 | 2022-2024 | |
| Travere Therapeutics, INC. | $63.46 | 2019-2022 | |
| Bard Access Systems, INC. | $56.83 | 2019 | |
| Sun Pharmaceutical Industries INC. | $56.19 | 2019-2023 | Yonsa |
| Accord Healthcare, INC. | $54.22 | 2022-2025 | |
| Procept Biorobotics Corporation | $49.46 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Davol INC. | $47.38 | 2023 | Arista Ah Flexitip |
| Astrazeneca Pharmaceuticals LP | $34.09 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.29 | 2022 | |
| Verity Pharmaceuticals INC. | $30.69 | 2023 | Trelstar |
| Foundation Medicine, INC. | $30.36 | 2021-2022 | |
| Rochester Medical Corporation | $27.85 | 2020-2022 | |
| Palette Life Sciences, INC. | $24.07 | 2022 | |
| Tolmar, INC. | $24.06 | 2023 | |
| Mission Pharmacal Company | $21.13 | 2019 | |
| Teleflex LLC | $20.99 | 2023 | Urolift |
| Immunitybio, INC. | $14.05 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $13.90 | 2023 | Bard Urinary Drainage Bag |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.